Metastasis-Related In Vitro Assays and Xenograft Models
Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis. To support research in this field, WuXi AppTec offers...
Continue Reading
Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis. To support research in this field, WuXi AppTec offers...
Continue Reading
WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc...
Continue Reading
As reported in Business Wire: DNA-Encoded Libraries (DELs) and NanoBRET Target Engagement Assays Accelerate Drug Discovery: “The authors demonstrate that...
Continue Reading
Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell...
Continue Reading
WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors...
Continue Reading
WuXi AppTec scientists recently contributed to a research article in Cell Chemical Biology demonstrating the successful conversion of ligands identified...
Continue Reading
Leverage our panel of in vitro immunology assays to accelerate your lead optimization efforts. WuXi AppTec offers a comprehensive platform of...
Continue Reading
WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs). Our comprehensive...
Continue Reading
To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell...
Continue Reading